Monopar Therapeutics (NASDAQ:MNPR) Downgraded to Sell Rating by Wall Street Zen

Monopar Therapeutics (NASDAQ:MNPR) was downgraded by equities researchers at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Saturday.

A number of other research firms also recently issued reports on MNPR. Piper Sandler set a $95.00 target price on shares of Monopar Therapeutics and gave the company an “overweight” rating in a research report on Thursday, September 25th. Jones Trading upgraded Monopar Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Friday, October 10th. HC Wainwright set a $105.00 price objective on Monopar Therapeutics and gave the company a “buy” rating in a report on Monday, September 29th. Oppenheimer set a $115.00 target price on Monopar Therapeutics and gave the stock an “outperform” rating in a research note on Thursday, October 2nd. Finally, Lake Street Capital began coverage on Monopar Therapeutics in a report on Tuesday, September 23rd. They set a “buy” rating and a $106.00 target price on the stock. Two investment analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $106.20.

Monopar Therapeutics Stock Up 1.1%

Shares of NASDAQ MNPR opened at $80.38 on Friday. Monopar Therapeutics has a 52 week low of $20.61 and a 52 week high of $105.00. The business’s 50 day moving average price is $85.31 and its 200 day moving average price is $55.98. The firm has a market cap of $536.94 million, a P/E ratio of -23.37 and a beta of 1.46.

Monopar Therapeutics (NASDAQ:MNPR) last posted its quarterly earnings results on Thursday, November 13th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.02). As a group, research analysts expect that Monopar Therapeutics will post -1.65 earnings per share for the current year.

Insider Buying and Selling

In other news, major shareholder Tactic Pharma Llc sold 550,229 shares of the business’s stock in a transaction that occurred on Wednesday, September 24th. The stock was sold at an average price of $63.61, for a total value of $35,000,066.69. Following the completion of the sale, the insider directly owned 272,026 shares in the company, valued at $17,303,573.86. The trade was a 66.92% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders own 20.50% of the company’s stock.

Institutional Investors Weigh In On Monopar Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the stock. TCG Crossover Management LLC purchased a new stake in Monopar Therapeutics in the 3rd quarter worth $12,496,000. Alyeska Investment Group L.P. acquired a new stake in shares of Monopar Therapeutics in the third quarter valued at about $998,000. Vivo Capital LLC purchased a new stake in shares of Monopar Therapeutics during the third quarter worth about $7,391,000. Ally Bridge Group NY LLC raised its position in shares of Monopar Therapeutics by 86.6% during the 3rd quarter. Ally Bridge Group NY LLC now owns 64,455 shares of the company’s stock worth $5,264,000 after purchasing an additional 29,918 shares during the last quarter. Finally, Deerfield Management Company L.P. purchased a new position in Monopar Therapeutics in the 3rd quarter valued at about $13,048,000. Institutional investors and hedge funds own 1.83% of the company’s stock.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.